Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA/EMA/Industry Action On PML Heralds New Foray Into Collaboration

Executive Summary

FDA, the European Medicines Agency and the pharmaceutical industry have embarked on a new cooperative effort to develop solutions to drug-related progressive multifocal leukoencephalopathy – a collaboration that could be a springboard for better disease/drug-specific cooperation.
Advertisement

Related Content

U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing
FDA, EMA Confidentiality Agreement Expanding Into "Clusters"
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

Topics

Advertisement
UsernamePublicRestriction

Register

PS053689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel